Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Protection of the lung from blast overpressure by stress wave decouplers, buffer plates or sandwich panels.

Sedman A, Hepper A.

J R Army Med Corps. 2019 Feb;165(1):22-26. doi: 10.1136/jramc-2017-000882. Epub 2018 Mar 19.

PMID:
29559499
2.

Modelling the blast environment and relating this to clinical injury: experience from the 7/7 inquest.

Hepper AE, Pope DJ, Bishop M, Kirkman E, Sedman A, Russell R, Mahoney PF, Clasper J.

J R Army Med Corps. 2014 Jun;160(2):171-4. doi: 10.1136/jramc-2014-000245. Epub 2014 Feb 19.

PMID:
24554527
3.

Comparison of Administrative Data Versus Infection Control Data in Identifying Central Line-Associated Bloodstream Infections in Children's Hospitals.

Harris JM 2nd, Gay JC, Neff JM, Patrick SW, Sedman A.

Hosp Pediatr. 2013 Oct;3(4):307-13. doi: 10.1542/hpeds.2013-0048.

4.

Determining the wounding effects of ballistic projectiles to inform future injury models: a systematic review.

Breeze J, Sedman AJ, James GR, Newbery TW, Hepper AE.

J R Army Med Corps. 2014 Dec;160(4):273-8. doi: 10.1136/jramc-2013-000099. Epub 2013 Jun 18. Review.

PMID:
24109099
5.

Self-cementing properties of oil shale solid heat carrier retorting residue.

Talviste P, Sedman A, Mõtlep R, Kirsimäe K.

Waste Manag Res. 2013 Jun;31(6):641-7. doi: 10.1177/0734242X13482033. Epub 2013 Mar 25.

PMID:
23528998
6.

Accuracy of hospital administrative data in reporting central line-associated bloodstream infections in newborns.

Patrick SW, Davis MM, Sedman AB, Meddings JA, Hieber S, Lee GM, Stillwell TL, Chenoweth CE, Espinosa C, Schumacher RE.

Pediatrics. 2013 Mar;131 Suppl 1:S75-80. doi: 10.1542/peds.2012-1427i.

PMID:
23457153
7.

Appropriate use of quality measures: Response to "Risk factors for hospital readmission within 30 days: A new quality measure for children with sickle cell disease".

Schwalenstocker E, Gay J, Muldoon J, Sedman A.

Pediatr Blood Cancer. 2009 Dec 15;53(7):1361; author reply 1362-4. doi: 10.1002/pbc.22212. No abstract available.

8.

Limitations in the agency for healthcare research and quality pediatric quality indicators result in flawed call for national benchmarks.

Scanlon MC, Harris JM, Levy F, Sedman A.

Pediatrics. 2008 Oct;122(4):903; author reply 903-4. doi: 10.1542/peds.2008-1974. No abstract available.

PMID:
18829820
9.

Evaluation of the agency for healthcare research and quality pediatric quality indicators.

Scanlon MC, Harris JM 2nd, Levy F, Sedman A.

Pediatrics. 2008 Jun;121(6):e1723-31. doi: 10.1542/peds.2007-3247. Epub 2008 May 12.

PMID:
18474532
10.

Implementing pediatric growth charts into an electronic health record system.

Rosenbloom ST, Qi X, Riddle WR, Russell WE, DonLevy SC, Giuse D, Sedman AB, Spooner SA.

J Am Med Inform Assoc. 2006 May-Jun;13(3):302-8. Epub 2006 Feb 24.

11.

Relevance of the Agency for Healthcare Research and Quality Patient Safety Indicators for children's hospitals.

Sedman A, Harris JM 2nd, Schulz K, Schwalenstocker E, Remus D, Scanlon M, Bahl V.

Pediatrics. 2005 Jan;115(1):135-45. Epub 2004 Dec 3.

PMID:
15579669
12.

Clinical redesign using all patient refined diagnosis related groups.

Sedman AB, Bahl V, Bunting E, Bandy K, Jones S, Nasr SZ, Schulz K, Campbell DA.

Pediatrics. 2004 Oct;114(4):965-9.

PMID:
15466092
13.

Pharmacokinetics of pregabalin in subjects with various degrees of renal function.

Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN.

J Clin Pharmacol. 2003 Mar;43(3):277-83.

PMID:
12638396
14.
15.

Improved growth in young children with severe chronic renal insufficiency who use specified nutritional therapy.

Parekh RS, Flynn JT, Smoyer WE, Milne JL, Kershaw DB, Bunchman TE, Sedman AB.

J Am Soc Nephrol. 2001 Nov;12(11):2418-26. Erratum in: J Am Soc Nephrol. 2002 May;13(5):1421-2.

16.

Drug interactions with clinafloxacin.

Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ.

Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52.

17.

Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Randinitis EJ, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ.

Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42.

18.

Quinapril and its metabolite quinaprilat in human milk.

Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Posvar EL, Sedman AJ.

Br J Clin Pharmacol. 2001 May;51(5):478-81.

19.

Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide.

Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB.

Am J Nephrol. 2001 Mar-Apr;21(2):128-33.

PMID:
11359020
20.

Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase.

Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM.

Eur J Drug Metab Pharmacokinet. 2000 Apr-Jun;25(2):97-101.

PMID:
11112089
21.

Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.

Flynn JT, Frisch K, Kershaw DB, Sedman AB, Bunchman TE.

Adv Perit Dial. 1999;15:269-72.

PMID:
10682116
22.

Improvement of glycemic control by CAPD with intraperitoneal insulin in a child with IDDM and ESRD.

Flynn JT, Kershaw DB, Sedman AB, Smoyer WE, Bunchman TE.

Adv Perit Dial. 1998;14:265-8.

PMID:
10649738
23.

Response to Lin and Ito. Effect of troglitazone on atorvastatin pharmacokinetics and pharmacodynamics

Loi CM, Sedman AJ.

Diabetes Care. 1999 Dec;22(12):2105-6. No abstract available.

24.

Gabapentin does not affect antipyrine clearance.

Allen E, Tsanaclis LM, Wroe SJ, Reece PA, Sedman AJ.

J Clin Pharmacol. 1999 Sep;39(9):934-5.

PMID:
10471984
25.

Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.

Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, Koup JR.

J Clin Pharmacol. 1999 Sep;39(9):920-6.

PMID:
10471982
26.

Effects of age and gender on single-dose pharmacokinetics of gabapentin.

Boyd RA, Türck D, Abel RB, Sedman AJ, Bockbrader HN.

Epilepsia. 1999 Apr;40(4):474-9.

27.

Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.

Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ.

J Clin Pharmacol. 1999 Apr;39(4):410-7.

PMID:
10197300
28.

Renal tubular dysgenesis in twins.

Barr M Jr, Sedman AB, Heidelberger KP.

Pediatr Nephrol. 1998 Jun;12(5):408-13.

29.

Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol.

Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ.

Neurology. 1998 Apr;50(4):1146-8.

PMID:
9566412
30.

Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.

Sramek JJ, Eldon MA, Posvar E, Feng MR, Jhee SS, Hourani J, Sedman AJ, Cutler NR.

Psychopharmacol Bull. 1998;34(1):93-9.

PMID:
9564205
31.

Effect of troglitazone on steady-state pharmacokinetics of digoxin.

Loi CM, Knowlton PW, Stern R, Randinitis EJ, Vassos AB, Koup JR, Sedman AJ.

J Clin Pharmacol. 1998 Feb;38(2):178-83.

PMID:
9549650
32.

Neoral induction in pediatric renal transplantation.

Bunchman TE, Parekh RS, Flynn JT, Smoyer WE, Kershaw DB, Valentini RP, Pontillo BJ, Sandvordenker J, Brown C, Sedman AB.

Pediatr Nephrol. 1998 Jan;12(1):2-5.

33.

Outcome of antineutrophil cytoplasmic autoantibodies-positive glomerulonephritis and vasculitis in children: a single-center experience.

Valentini RP, Smoyer WE, Sedman AB, Kershaw DB, Gregory MJ, Bunchman TE.

J Pediatr. 1998 Feb;132(2):325-8.

PMID:
9506649
34.

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ.

J Clin Pharmacol. 1997 Dec;37(12):1114-20.

PMID:
9506006
35.

Beneficial effect of Sandoglobulin upon allograft survival in the pediatric renal transplant recipient.

Bunchman TE, Parekh RS, Kershaw DB, Smoyer WE, Flynn JT, Valentini RP, Sedman AB.

Clin Transplant. 1997 Dec;11(6):604-7.

PMID:
9408693
36.

Pharmacokinetics of pirmenol enantiomers and pharmacodynamics of pirmenol racemate in patients with premature ventricular contractions.

Janiczek N, Smith DE, Chang T, Sedman AJ, Stringer KA.

J Clin Pharmacol. 1997 Jun;37(6):502-13.

37.

Future workforce needs for pediatric nephrology: an analysis of the nephrology workforce and training requirements by the Workforce Committee of the American Society of Pediatric Nephrology.

Stapleton FB, Andreoli S, Ettenger R, Kamil E, Sedman A, Chesney R.

J Am Soc Nephrol. 1997 May;8(5 Suppl 9):S5-8. No abstract available.

38.

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.

Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL.

Clin Pharmacol Ther. 1996 Dec;60(6):687-95.

PMID:
8988072
39.
40.

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.

Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ.

J Clin Pharmacol. 1996 Aug;36(8):728-31.

PMID:
8877677
41.

Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.

Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST.

Biopharm Drug Dispos. 1996 Aug;17(6):459-70.

PMID:
8866037
42.

Nutritional management of the child with mild to moderate chronic renal failure.

Sedman A, Friedman A, Boineau F, Strife CF, Fine R.

J Pediatr. 1996 Aug;129(2):s13-8. Review.

PMID:
8765644
43.
44.

Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.

Yang BB, Hounslow NJ, Sedman AJ, Forgue ST.

J Clin Pharmacol. 1996 Apr;36(4):356-60.

PMID:
8728350
45.

Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis.

Gregory MJ, Smoyer WE, Sedman A, Kershaw DB, Valentini RP, Johnson K, Bunchman TE.

J Am Soc Nephrol. 1996 Apr;7(4):543-9.

46.

Inhibition of tacrine oral clearance by cimetidine.

Forgue ST, Reece PA, Sedman AJ, deVries TM.

Clin Pharmacol Ther. 1996 Apr;59(4):444-9.

PMID:
8612390
47.

Effect of age and gender on pharmacokinetics of atorvastatin in humans.

Gibson DM, Bron NJ, Richens A, Hounslow NJ, Sedman AJ, Whitfield LR.

J Clin Pharmacol. 1996 Mar;36(3):242-6.

PMID:
8690818
48.

Clinical pharmacology and first-time-in-man studies: the FDA levels the playing field.

Luderer J, Piergies AA, Jorkasky D, Sedman A, Reele S, Froehlich J, Cavanaugh J, Steinman GL.

J Clin Pharmacol. 1996 Mar;36(3):187-8. No abstract available.

PMID:
8690810
49.

Experimental evaluation of a rig to simulate the response of the thorax to blast loading.

Cooper GJ, Pearce BP, Sedman AJ, Bush IS, Oakley CW.

J Trauma. 1996 Mar;40(3 Suppl):S38-41. No abstract available.

PMID:
8606418
50.

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.

Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.

Biol Psychiatry. 1995 Dec 1;38(11):742-6.

PMID:
8580227

Supplemental Content

Loading ...
Support Center